QQ客服 官方微博 反馈留言

浏览/检索结果: 共13条，第1-10条 帮助 限定条件 专题：山东大学    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial 期刊论文 TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 卷号: 8, 期号: 5, 页码: 575-+ 作者:  Wang, Lili;  He, Zhen;  Yang, Sen;  Tang, Hong;  Wu, Yufeng 收藏  |  浏览/下载：5/0  |  提交时间：2019/12/11 Non-small cell lung cancer (NSCLC)  anlotinib  antiangiogenic therapy   Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial 期刊论文 ONCOLOGIST, 2019, 卷号: 24, 期号: 8, 页码: E702-E708 作者:  Zhou, Ai-Ping;  Bai, Yuxian;  Song, Yan;  Luo, Hong;  Ren, Xiu-Bao 收藏  |  浏览/下载：27/0  |  提交时间：2019/12/11 Anlotinib  Metastatic renal cell cancer  Phase II clinical trial   Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303 期刊论文 THORACIC CANCER, 2019, 卷号: 10, 期号: 3, 页码: 551-556 作者:  Si, Xiaoyan;  Zhang, Li;  Wang, Hanping;  Zhang, Xiaotong;  Wang, Mengzhao 收藏  |  浏览/下载：25/0  |  提交时间：2019/12/11 Adverse event  anlotinib  multi-target tyrosine kinase inhibitor  non-small cell lung cancer   Clinical outcomes of patients with or without common AEs in anlotinib cohort: Subgroup analysis of the ALTER0303 trial. 会议论文 Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), MAY 31-JUN 04, 2019 作者:  Wang Zhe-Hai;  Han, Baohui;  Li, Kai;  Cheng, Ying;  Liu, Jie 收藏  |  浏览/下载：8/0  |  提交时间：2019/12/31 The efficacy of anlotinib in squamous cell carcinoma (SCC) patients with or without hypertension in ALTER0303: Anlotinib as a third-line therapy in patients with advanced non-small cell lung cancer (NSCLC). 会议论文 Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), MAY 31-JUN 04, 2019 作者:  Shi, Jianhua;  Han, Baohui;  Li, Kai;  Wang, Qiming;  Zhang, Li 收藏  |  浏览/下载：5/0  |  提交时间：2019/12/31 Management of Anlotinib-Related Adverse Events: Data From ALTER 0303 期刊论文 JOURNAL OF THORACIC ONCOLOGY, 2018, 卷号: 13, 期号: 10, 页码: S505-S506 作者:  Si, X.;  Zhang, L.;  Wang, H.;  Zhang, X.;  Wang, M. 收藏  |  浏览/下载：3/0  |  提交时间：2019/12/11 non-small cell lung cancer  adverse event  Anlotinib   Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer 期刊论文 LUNG CANCER, 2018, 卷号: 122, 页码: 32-37 作者:  Si, Xiaoyan;  Zhang, Li;  Wang, Hanping;  Zhang, Xiaotong;  Wang, Mengzhao 收藏  |  浏览/下载：2/0  |  提交时间：2019/12/11 Anlotinib  Non-small cell lung cancer  Quality of life   Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer The ALTER 0303 Phase 3 Randomized Clinical Trial 期刊论文 JAMA ONCOLOGY, 2018, 卷号: 4, 期号: 11, 页码: 1569-1575 作者:  Han, Baohui;  Li, Kai;  Wang, Qiming;  Zhang, Li;  Shi, Jianhua 收藏  |  浏览/下载：1/0  |  提交时间：2019/12/11 Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment 期刊论文 CANCER BIOLOGY & MEDICINE, 2018, 卷号: 15, 期号: 4, 页码: 443-451 作者:  Wang, Jing;  Zhao, Yizhuo;  Wang, Qiming;  Zhang, Li;  Shi, Jianhua 收藏  |  浏览/下载：2/0  |  提交时间：2019/12/11 The Impact of Anlotinib on Quality of Life in Patients with Advance NSCLC: Post-Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303) 期刊论文 JOURNAL OF THORACIC ONCOLOGY, 2018, 卷号: 13, 期号: 10, 页码: S505-S505 作者:  Si, X.;  Zhang, L.;  Wang, H.;  Zhang, X.;  Wang, M. 收藏  |  浏览/下载：2/0  |  提交时间：2019/12/11 Anlotinib  non-small cell lung cancer  quality of life